中药注射剂龙头业绩失守：上市十年首亏超10亿元，珍宝岛业绩被什么击穿｜ 中药锈带

Core Viewpoint - The traditional Chinese medicine company Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has reported its first loss in ten years, highlighting the challenges faced by the industry during a significant transformation period [2][4]. Financial Performance - Zhenbaodao expects a net profit loss of approximately -1.173 billion to -1.012 billion yuan for the fiscal year 2025, marking a dramatic shift from profit to loss compared to the previous year [2]. - The company's net profit has decreased by 330.94% to 367.68% year-on-year, setting a record for the worst performance in its history [2]. - In the first half of 2025, the company's revenue plummeted by 57.04% to 713 million yuan, with a net loss of 78.29 million yuan, a 119.9% decline year-on-year [6]. Market Challenges - The decline in performance is attributed to several factors, including lower-than-expected sales of core products, price reductions, and significant credit impairment losses of approximately 395 million yuan [4][6]. - The company’s core products, which account for over 70% of its revenue, have been affected by national procurement policies and ongoing healthcare cost controls [4][5]. Strategic Issues - Zhenbaodao's heavy reliance on traditional products and slow innovation has led to strategic difficulties, forcing the company to drastically cut sales and R&D expenses to maintain cash flow [4][6]. - The company’s R&D expenditure has significantly decreased by 52.64% to 37.99 million yuan, representing only 2.60% of its revenue, which is well below the industry average [7]. Governance Concerns - The company faced criticism from the Shanghai Stock Exchange for a 425 million yuan equity transfer that bypassed required approval processes, raising governance concerns [8][9]. - Despite the financial downturn, Zhenbaodao continued to distribute dividends totaling 141 million yuan in 2024, leading to market skepticism regarding the management's priorities and potential wealth transfer to major shareholders [9]. Industry Outlook - The significant loss signals a broader trend where traditional Chinese medicine companies relying on single products and inefficient operations may struggle to survive as procurement practices become more standardized [10]. - Zhenbaodao is attempting to adjust its strategy by focusing on innovation in traditional Chinese medicine, biopharmaceuticals, and chemical drugs, while also restructuring its marketing approach [10].